Home / Stock ratings / Healthcare Stocks / MDT
Stock rating · Electromedical & Electrotherapeutic Apparatus
Medtronic plc (MDT) Stock Rating & Analysis
As of November 20, 2026, MELANY rates Medtronic plc 71 out of 100 (Highest Conviction). Its highest factor score is catalyst setup at 100, and its lowest is macro fit at 50.
MDT · composite score
About Medtronic plc
Medtronic, among the largest medical-device companies, develops and manufactures therapeutic devices for chronic diseases, including pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. It markets mainly to healthcare institutions and physicians in the US, Western Europe, and Japan, with foreign sales making up roughly 50% of total sales.
Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).
Why MDT scores 71/100
MDT's 8 factor scores run from 50 to 100, and 3 of them sit above its composite of 71. Here is how MDT breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 15.6x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 65%
Direction and relative strength of the recent share-price trend.
- Price +5.6% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
- Earnings in 3 days (strong beat history)
What Wall Street price targets and revisions are signalling.
- Institutional net buying +5.5%
Near-term events that could move the stock.
- Earnings in 3 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How MDT compares
As of November 20, 2026, Medtronic plc ranks 2nd of 20 in Healthcare Stocks, where the average score is 62.
Key risks for MDT
- Earnings report in 3 days, binary outcome can move 10%+ either way
- Performance partly driven by Healthcare sector, rotation away from this theme would hurt
Sector and theme context
Medtronic plc sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds MDT's momentum and catalyst factors above.
MDT trade plan (Pro)
MELANY has a full position plan for Medtronic plc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates MDT
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Medtronic plc's 71/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about MDT
Is Medtronic plc (MDT) a buy?
As of 2026-11-20, MELANY rated Medtronic plc Highest Conviction with a composite score of 71/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
How does MDT rank against similar companies?
As of November 20, 2026, Medtronic plc ranks 2nd of 20 in MELANY's Healthcare Stocks list, where the average score is 62. Among the other names in the list, the highest scores belong to REGN (74) and LLY (68).
Should I buy Medtronic plc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Medtronic plc (MDT) Highest Conviction with a composite of 71/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the MDT stock price forecast?
MELANY does not publish price targets or forecasts for MDT. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 71/100 across eight factors for Medtronic plc, and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for MDT as of 2026-11-20: its analyst sentiment factor is 74/100 (Institutional net buying +5.5%), and its price momentum factor is 71/100.
Is MDT stock overvalued or undervalued?
MELANY's valuation factor currently reads 61/100 for Medtronic plc, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives MDT's read.
What price should I buy MDT at?
Rather than chasing the current price, MELANY computes a smart entry zone for MDT: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying MDT stock?
The top risks MELANY currently flags for Medtronic plc: Earnings report in 3 days, binary outcome can move 10%+ either way; Performance partly driven by Healthcare sector, rotation away from this theme would hurt. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Medtronic plc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 64/100 for Medtronic plc, and earnings track record, at 70/100. The 71/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will MDT stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 71/100 for MDT right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this MDT rating?
The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores MDT as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, MDT included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.